Glioblastoma survival has not improved in the last 30 years and there is an urgent need to develop novel therapeutic approaches for it.

Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor ...

Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished ...

Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations revealed findings from the preclinical evaluation of 1H5, a novel monoclonal antibody (mAb) candidate that inhibits ...

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor ...

Memorial Sloan Kettering Cancer Center-led researchers have identified a small molecule called gliocidin that kills ...

This discovery is important because until now, we have not had compelling evidence that temozolomide improves overall survival in grade 2 gliomas." David Schiff, MD, lead investigator, the ...

DIPG, which stands for diffuse intrinsic pontine glioma, is considered a universally fatal disease. It can wreak its havoc quickly, and the five-year survival rate is below 1%. “These are ...

Used in conjunction with the oral sonosensitizing agent 5-ALA, the sonodynamic therapy led to a median OS of 15.7 months in ...